HESKA CORPORATION (NASDAQ:HSKA) Files An 8-K Regulation FD DisclosureItem 7.01
Regulation FD Disclosure.
On October 25, 2018, the Board of Directors of Heska Corporation, a Delaware corporation (the “Company”) appointed Mr. Scott W. Humphrey to serve as Chair of the Board of Directors. Mr. Humphrey has served the Company as a director since June 2017, and he will continue to serve as a member of the Compensation and Audit Committees of the Board of Directors. Mr. Humphrey is the successor in such role to Ms. Sharon J. Larson, who has served as Chair of the Board of Directors since October 2015. Ms. Larson has served the Company as a director since July 2011, and she will continue to serve as a member of the Board of Directors, as Chair of its Corporate Governance Committee, and as a member of its Audit Committee.
About HESKA CORPORATION (NASDAQ:HSKA)
Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company focuses on the canine and feline companion animal health markets. Its segments include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals. It offers blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing.
